Everything below concerns Toll-like receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-10. Numbers and descriptions here follow the published literature rather than marketing material.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
In 2025, CERN's ALICE experiment team announced that over the previous decade, they had used the Large Hadron Collider to replicate the 2002 SPS mechanisms at higher energies. A total of roughly 260 billion gold nuclei were created over three experimental runs, a minuscule amount of about 90 picograms. Startup Marathon Fusion proposes a theoretical way to make gold from mercury: use a nuclear fusion reactor to bombard mercury with high-energy neutrons, specifically 198Hg, an isotope with 10% abundance. This creates the unstable 197Hg, which then decays into stable gold (197Au) with a half-life of approximately 64 hours.
On September 2, 2022, in a nationally broadcast Philadelphia speech, Biden called for a "battle for the soul of the nation". Off camera, he called Trump supporters "semi-fascists", which Republican commentators denounced. A predicted Republican wave election did not materialize and the race for U.S. Congress control was much closer than expected, with Republicans securing a slim majority of 222 seats in the House of Representatives, and the Democratic caucus keeping control of the U.S. Senate. It was the first midterm election since 1986 in which the incumbent president's party achieved a net gain in governorships, and the first since 1934 in which the president's party lost no state legislative chambers. Democrats credited Biden for their unexpectedly strong performance, but they likely overperformed for other reasons, including the Supreme Court overturning Roe v. Wade and poor Republican candidate quality in many races.
Neuroleptic, originating from the Ancient Greek terms νεῦρον ('neuron') and λαμβάνω ('to take hold of')—thus meaning 'which takes the nerve'—refers both to common neurological effects and to side-effects. An estimated 1.7% of adults in the United States take antipsychotics, according to a 2018 study.
Sources: en.wikipedia.org
Current treatment of dermatomyositis relies on immunosuppressive agents such as corticosteroids, methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, and cyclosporine, with intravenous immunoglobulin (IVIG) widely used for refractory or severe disease. Rituximab remains an important therapeutic option despite mixed clinical trial results. Emerging targeted therapies, including Janus kinase (JAK) inhibitors and agents targeting the type I interferon pathway, such as dazukibart, have demonstrated promising efficacy. Novel approaches such as CD19 chimeric antigen receptor (CAR) T-cell therapy, plasma cell–directed therapies, and neonatal Fc receptor (FcRn) inhibitors, such as efgartigimod, are also showing encouraging results, offering the potential for sustained treatment-free disease control in the case of CD19 CAR-T cell therapy. Overall, with timely diagnosis and appropriate treatment, the prognosis of DM is generally favorable. About one in 100,000 people receive a new diagnosis of dermatomyositis each year. The condition usually occurs in those in their 40s and 50s with women being affected more often than men. People of any age, however, may be affected. The condition was first described in the 1800s.
In his work with the late Hans Eysenck and subsequently with Con Stough on the role of basic information processing speed in human intelligence, he used ERP complexity measures to argue for a modification to the Hendrickson and Hendrickson error or "string theory" (so named as pins and string were used to make the measurements of EEG output) model of ability, to include a controlling role of attention. In related work on reaction time, he introduced a novel modification to the Jensen box, again controlling the role of attention in this task, and suggesting that under these conditions, intelligence is, as Arthur Jensen proposed, related to the rate of information processing defined in Fitts Law and using Claude Shannon's information metrics. At the University of Edinburgh he has investigated individual differences in intelligence, memory, and the genetic and environmental influences on social behaviours, such as coalition affiliation, politics, and altruism. Working with Ian Deary, Paul Irwing, and Geoff Derr, he reported evidence for substantial gender differences in intelligence in the form of much larger variance amongst males than amongst females, with more boys and men scoring in both the extreme high range, and in the extreme low range.
7 and Transitional Provisions) Order 1993 (S.I. 1993/2229) National Assistance (Assessment of Resources) (Amendment No.2) Regulations 1993 (S.I. 1993/2230) National Curriculum Council and School Examinations and Assessment Council (Designation of Staff) Order 1993 (S.I. 1993/2231) Export of Goods (Control) (Haiti) (Revocation) Order 1993 (S.I. 1993/2232) Motor Vehicles (Competitions and Trials) (Amendment) Regulations 1993 (S.I. 1993/2233) Road Traffic (Special Parking Areas) (London Boroughs of Bromley, Hammersmith and Fulham and Lewisham) (London Borough of Wandsworth) (Amendment) Order 1993 (S.I. 1993/2237) Housing (Extension of Right to Buy) Order 1993 (S.I. 1993/2240) Housing (Preservation of Right to Buy) Regulations 1993 (S.I. 1993/2241) Valuation Timetable (Scotland) Amendment (No.3) Order 1993 (S.I. 1993/2242) Housing (Right to Buy Delay Procedure) (Prescribed Forms) (Amendment) Regulations 1993 (S.I. 1993/2245) Housing (Right to Buy) (Prescribed Forms) (Amendment) Regulations 1993 (S.I. 1993/2246) Law Reform (Miscellaneous Provisions) (Scotland) Act 1990 (Commencement No.12) Order 1993 (S.I. 1993/2253) Public Trusts (Reorganisation) (Scotland) (No.2) Regulations 1993 (S.I. 1993/2254) Fish Health (Amendment) Regulations 1993 (S.I. 1993/2255) Royal National Hospital for Rheumatic Diseases National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2256) St Peter's Hospital National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.